NCT00237718View on ClinicalTrials.gov

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
End-stage Renal Disease
Interventions
DRUG

Alpha, gamma, beta, and delta (mixed) tocopherols

approximately 666 IU daily (1 pill) for 6 months

DRUG

Alpha lipoic acid

600 mg daily (2 pills 300 mg each) for 6 months

DRUG

Placebo

placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months

DRUG

Placebo

placebo for alpha lipoic acid; 2 pills daily for 6 months

Trial Locations (1)

37215

Fresenius Medical Care North America, Nashville

All Listed Sponsors
collaborator

Fresenius Medical Care North America

INDUSTRY

lead

Vanderbilt University

OTHER

NCT00237718 - Provision of Antioxidant Therapy in Hemodialysis (PATH) Study | Biotech Hunter | Biotech Hunter